November 16, 2016 - By Darrin Black · 0 Comments
Pluristem Therapeutics Inc (NASDAQ:PSTI) institutional sentiment decreased to 0.67 in Q2 2016. Its down -0.09, from 0.76 in 2016Q1. The ratio dived, as 8 investment managers opened new and increased positions, while 12 cut down and sold their equity positions in Pluristem Therapeutics Inc. The investment managers in our partner’s database reported: 2.97 million shares, down from 3.13 million shares in 2016Q1. Also, the number of investment managers holding Pluristem Therapeutics Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 8 Increased: 6 New Position: 2.
Pluristem Therapeutics Inc. is a developer of placenta cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The company has a market cap of $125.05 million. The Company’s lead indications are critical limb ischemia , recovery after surgery for femoral neck fracture and acute radiation syndrome. It currently has negative earnings. The Company’s activities are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies.
It is down 12.43% since April 14, 2016 and is downtrending. It has underperformed by 17.12% the S&P500.
According to Zacks Investment Research, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells.”
Bank Of America Corp De holds 0% of its portfolio in Pluristem Therapeutics Inc. for 125 shares. Barclays Plc owns 715,965 shares or 0% of their US portfolio. Moreover, California Public Employees Retirement System has 0% invested in the company for 181,700 shares. The Illinois-based Citadel Advisors Llc has invested 0% in the stock. Citigroup Inc, a New York-based fund reported 1,040 shares.#img1#
Ratings analysis reveals 100% of Pluristem Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Pluristem Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3 while the high is $8. The stock’s average target of $4.17 is 169.03% above today’s ($1.55) share price. PSTI was included in 4 notes of analysts from August 14, 2015. Maxim Group maintained Pluristem Therapeutics Inc. (NASDAQ:PSTI) rating on Tuesday, December 22. Maxim Group has “Buy” rating and $3 price target. The company was reinitiated on Tuesday, July 19 by H.C. Wainwright. The stock of Pluristem Therapeutics Inc. (NASDAQ:PSTI) has “Buy” rating given on Friday, August 14 by MLV. The rating was maintained by Maxim Group with “Buy” on Tuesday, August 18.
Pluristem Therapeutics Inc., incorporated on May 10, 2001, is a developer of placenta cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. The Company’s activities are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black